Spots Global Cancer Trial Database for TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)

Official Title: TheraSphere HUD For Treatment of Unresectable HCC

Study ID: NCT00683631

Conditions

Hepatocellular Carcinoma

Interventions

TheraSphere HUD

Study Description

Brief Summary: The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.

Detailed Description: Surgical resection of the affected portion of the liver offers the best chance for disease-free survival in patients with primary liver cancer (hepatocellular carcinoma (HCC)). Unfortunately, most of these patients present with disease that is not amenable to surgery (multifocal disease) or have other medical contraindications to surgery (limited hepatic reserve related to advanced cirrhosis or chronic hepatitis). Fewer than 15% of HCC patients are suitable surgical candidates. The objective of treatment with TheraSphere is to selectively administer a potentially lethal dose of radioactive material to cancerous tissue in the liver of patients with HCC. This type of regional therapy may have several advantages over systemically administered treatments and may also be of value as a 'bridging' treatment for HCC patients awaiting a donor organ for liver transplantation.